Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Other

Cornell Research Foundation Inc.

The New York Hospital-cornell Medical Center

Matthew J Scanlan

Yao-tseng Chen

Lloyd J Old

Ali O Gure

Alexander Knuth

Elisabeth Stockert

Elke Jager

Lloyd Old

Dirk Jager

Gerd J Ritter

Jan Wouter Drijfhout

Elke Jäger

Michael Pfreundschuh

Ugur Sahin

Ozlem Tureci

Elke J&auml;ger

Elizabeth Stockert

Cynthia H Scanlan, Legal Representative

Knuth Alexander

Sang-Yull Lee

Solam Tsang

Wolfgang J Rettig

Pilar Garin-Chesa

Ivan Tarasovich Gout

Achim Jungbluth

Barbara D Williamson

Barry C Picker, Legal Representative

Alex Knuth

Ali Gur&eacute;

Yao-Tseng Chen

The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.

Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein

Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.

A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same

The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.

Human sarcoma-associated antigens

The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.

Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein

Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof

The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.

Breast cancer antigens

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

Small cell lung cancer associated antigens and uses therefor

The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof

The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.

Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses

Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53

Growing community of inventors

New York, NY, United States of America

Matthew J Scanlan